Radius Health

What Radius Health does

Radius Health is a commercial biopharmaceutical company specializing in bone health therapeutics, with a focus on osteoporosis treatment. Its core product, TYMLOS (abaloparatide), is a novel parathyroid hormone related peptide (PTHrP(1-34)) analog and the first FDA-approved PTHrP analog for osteoporosis, delivered as an 80-microgram daily subcutaneous injection via a single-patient multi-use prefilled pen over a 30-day period. The portfolio also includes BINOSTO (alendronate sodium effervescent tablet), a once-weekly oral osteoporosis therapy licensed from EffRx Pharmaceuticals, which addresses patients who have difficulty swallowing pills. The company serves postmenopausal women and men with osteoporosis at high risk for fracture, with clinical evidence including an 86% relative risk reduction in new vertebral fractures versus placebo in the ACTIVE trial.

The company's underlying technology is differentiated at the molecular level: abaloparatide selectively activates the PTH1 receptor as a bone-forming (anabolic) agent, distinct from teriparatide (PTH 1-34), with real-world evidence showing superior hip fracture reduction (1.1% vs 1.4%, HR 0.83). Five TYMLOS patents, co-held with Ipsen Pharma S.A.S., were upheld in 2025 litigation with the latest expiring April 30, 2038, providing long-term exclusivity.

Radius operates a hybrid commercial model. In the US, it sells directly through authorized distributor networks and specialty pharmacy channels (Medvantx), targeting specialist physicians treating osteoporosis, while supplementing access through the Radius Assist patient assistance program. Internationally, the company pursues a licensing model, granting commercialization rights to Theramex (Europe, Mexico, Canada, South Africa, Israel, Russia, Australia, Brazil), Pharmanovia (Asia Pacific), and Teijin Pharma (Japan), generating upfront, milestone, and tiered royalty revenue. Additional royalty and milestone streams come from the 2020 elacestrant (ORSERDU) licensing to Menarini Group, partially monetized via a $130M sale to DRI Healthcare. Originally a NASDAQ-listed company (RDUS), Radius was taken private in August 2022 by Gurnet Point Capital and Patient Square Capital, with B-FLEXION Life Sciences consolidating full ownership in January 2026. In March 2026, Radius completed its merger with Paratek Pharmaceuticals, integrating TYMLOS, BINOSTO, NUZYRA, and XHANCE into a diversified specialty pharmaceutical platform projected to generate nearly $1 billion in 2026 revenue.

Name

Radius Health

Legal name

Radius Health, Inc.

Website

https://radiuspharm.com

Company type

Private

Founded year

2013

Operating status

Acquired

Headcount range

251–500 employees

Short description

Radius Health is a commercial biopharmaceutical company specializing in bone health therapeutics, primarily offering TYMLOS (abaloparatide) and BINOSTO for osteoporosis treatment. The company serves postmenopausal women and men at high fracture risk through direct US sales and international licensing partnerships.

Ownership category

akta.pro rank

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Pharmaceutical Product Sales: Direct sales of TYMLOS (abaloparatide injection) and BINOSTO (alendronate sodium) in the US market for osteoporosis treatment.
2. Licensing Royalties and Milestones: Royalty streams and milestone payments from licensing agreements with Menarini Group for elacestrant (ORSERDU), Theramex for ELADYNOS in Europe and other territories, Pharmanovia for Asia Pacific, and Teijin for Japan. DRI Healthcare acquired a portion of elacestrant royalties for $130M upfront plus $10M.
3. Merger Revenue Impact: Following completion of merger with Paratek Pharmaceuticals in March 2026, the combined company is expected to generate nearly $1 billion in annual revenue in 2026, spanning seven therapeutic areas.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Radius Health is a commercial biopharmaceutical company that develops, manufactures, and markets drug therapies for osteoporosis and related bone health conditions. Its core products are TYMLOS (abaloparatide), a parathyroid hormone-related peptide analog delivered via prefilled pen for high-risk osteoporosis patients, and BINOSTO (alendronate sodium), an effervescent once-weekly oral tablet for osteoporosis treatment. The company also operates the Radius Assist patient assistance program to support patient access.

Product overview

Radius Health is a commercial biopharma company specializing in bone health therapeutics. The company's product portfolio centers on TYMLOS® (abaloparatide injection), a parathyroid hormone related peptide analog for osteoporosis treatment, which received initial FDA approval in 2017 for postmenopausal women and was expanded in 2022 to include men. BINOSTO® (alendronate sodium effervescent tablet) was added in 2023 as an exclusive licensing arrangement, providing a complementary once-weekly oral treatment option for osteoporosis patients. The portfolio is complemented by Radius Assist, a patient assistance program supporting access to TYMLOS® for eligible patients. In March 2026, Radius Health completed a merger with Paratek Pharmaceuticals, integrating TYMLOS® alongside Paratek's NUZYRA® and XHANCE® products into a diversified specialty pharmaceutical platform generating nearly $1 billion in projected 2026 revenue.

Differentiator

Problem solved

Functional benefit

Brands

• Radius Assist: Patient assistance program providing TYMLOS (abaloparatide) injection therapy at no cost to qualified patients in need

Products and services

• TYMLOS (abaloparatide injection) TYMLOS is an abaloparatide injection, a parathyroid hormone related peptide (PTHrP) analog approved by the FDA for treating postmenopausal women and men with osteoporosis at high risk for fracture. Administered as an 80 microgram subcutaneous injection once daily via a single-patient multi-use prefilled pen over a 30-day period.
• BINOSTO (alendronate sodium) BINOSTO is an alendronate sodium effervescent tablet for oral solution, indicated for treating osteoporosis in postmenopausal women and increasing bone mass in men with osteoporosis. Provides a once-weekly treatment option particularly for patients who may have difficulty swallowing pills.
• ELADYNOS (abaloparatide) ELADYNOS is the European brand name for abaloparatide, commercialized by Theramex under licensing agreement in the European Economic Area, United Kingdom, Australia, Brazil, Mexico, Canada, Israel, South Africa, and Russia.

Quantifiable outcome

• 86% relative risk reduction in new vertebral fractures vs placebo
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Four partnerships are on record, tiered core and major.

• Paratek PharmaceuticalscoreStrategic or Co-development Partner · 18 March 2026Merger combination completed March 2026, creating diversified specialty pharmaceutical company expected to generate nearly $1 billion revenue in 2026. TYMLOS added to Paratek's portfolio alongside NUZYRA and XHANCE. Combined company spans infectious disease, podiatry, otolaryngology, allergy, rheumatology, endocrinology, and gynecology.
• PharmanoviamajorChannel Partner/ Reseller/ DistributorLicensing agreement for exclusive commercialization rights to abaloparatide in China, Singapore, Thailand, Indonesia, Vietnam, Taiwan, Hong Kong, Malaysia, Macau and Philippines. Radius eligible for upfront payment, regulatory and commercial milestones, plus tiered royalties on net sales. Announced January 2, 2025.
• TheramexmajorChannel Partner/ Reseller/ DistributorExpanded licensing agreement granting exclusive commercialization rights for ELADYNOS (abaloparatide) in Mexico, Canada, Israel, South Africa, and Russia. Theramex also commercializes ELADYNOS in EEA, UK, Australia, and Brazil. European approval December 2022, Australian approval November 2024. Radius receives upfront, milestone payments, and tiered royalties.
• EffRx Pharmaceuticals, S.A.majorChannel Partner/ Reseller/ DistributorExclusive licensing and distribution agreement for U.S. rights to BINOSTO (alendronate sodium effervescent tablet) for osteoporosis. EffRx supplies product to Radius. Expands Radius bone health portfolio with second osteoporosis treatment product.

Scale indicators5 records

Recent moves2 records

Direct peers

• Amgen: Amgen markets Prolia (denosumab) and co-markets Evenity (romosozumab) with UCB, both leading bone-forming/resorption osteoporosis therapies. Amgen is a direct competitor to Radius in the high-risk osteoporosis space and shares the specialist physician channel that Radius targets.
• Eli Lilly: Eli Lilly markets Forteo (teriparatide), the legacy parathyroid hormone analog and TYMLOS's principal head-to-head competitor. Real-world evidence directly compares abaloparatide to teriparatide, making Lilly a directly comparable peer in the anabolic osteoporosis category.
• UCB: UCB co-develops and co-markets Evenity (romosozumab) with Amgen, a sclerostin antibody for postmenopausal osteoporosis. UCB is a direct competitor in the bone-forming osteoporosis space that Radius targets with TYMLOS.
• Theramex: Theramex is Radius's exclusive commercialization partner for ELADYNOS (abaloparatide) across Europe, UK, Australia, Brazil, Mexico, Canada, Israel, South Africa, and Russia. Theramex operates a women's health specialty pharma platform that is directly comparable to Radius's bone-health franchise.
• Paratek Pharmaceuticals: Paratek is the merger partner that combined with Radius Health in March 2026 to form the current combined specialty pharma platform. Paratek's portfolio (NUZYRA, XHANCE) overlaps with Radius's commercial-stage specialty pharma business model and shares therapeutic-area adjacency.

Broad incumbents

• Menarini Group: Menarini holds global development and commercialization rights to Radius's elacestrant (ORSERDU) and operates as a broad specialty pharma incumbent across multiple therapeutic areas including oncology and women's health, directly comparable to Radius's commercialization model.
• Currax Pharmaceuticals: Currax is a privately held specialty pharma company that has overlapping executive talent (Radius's current SVP/General Counsel joined from Currax). It operates as a broader specialty pharma player in adjacent therapeutic areas, comparable as a similarly sized specialty pharma platform.
• BioDelivery Sciences International: BioDelivery Sciences is a specialty pharma with overlapping leadership background (Al Medwar previously served as EVP). It is comparable as a similarly structured specialty pharmaceutical commercialization platform with branded prescription products.
• Recordati Rare Diseases: Recordati Rare Diseases is a specialty pharma company where Radius's SVP Medical Operations previously served as VP of Medical Affairs. It is a comparable specialty pharma platform operating in rare and specialty therapeutic areas with similar commercial infrastructure.

Regional players

• Teijin Pharma: Teijin Pharma holds Japan commercialization rights for ELADYNOS (abaloparatide). As a regional specialty pharma partner commercializing the same asset in Japan, Teijin is directly comparable as a regional peer operating in the same therapeutic category.

Market position

Strengths5 records

Weaknesses5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/radius_health
• YouTubeyoutube.com/radiushealth
• LinkedInlinkedin.com/company/radius-health-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds9 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Radius Health